▎ 摘　　要

NOVELTY - Use of hybrid nanoparticles, preferably highly reduced graphene oxide (HRG)-manganese oxide as photodynamic therapy agent and imaging agent for cancer, is claimed. USE - Hybrid nanoparticles for use as photodynamic therapy agent for treating cancer and/or as contrast agent for imaging cancer cells (claimed). Test details are described but no results given. ADVANTAGE - The hybrid nanoparticles are biocompatible and do not cause cytotoxicity at normal physiological conditions. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for synthesis the hybrid nanoparticle, which involves: a. synthesising manganese oxide nanoparticles; b. synthesising highly reduced HRG nanoparticles; and c. preparing highly reduced HRG-manganese oxide hybrid nanoparticles by milling manganese oxide nanoparticles and highly reduced HRG nanoparticles.